The therapeutic is not a no-go, just that to get definitive data on this opportunity there will need to be another trial.
To be able to run a therapeutic field trial you have to first run the current Phase 2b trial.
It is the preventative trial that is key to commercial success - in the end it really doesn't matter too much if ISLA-101 has activity as a therapeutic as the market is for a preventive treatment is probably 100x larger. You could make a good case that therapeutic activity is a distraction as it would be best to rule out that it works this way so that all clinical development concentrates on prevention.
Ann: Successful Phase 2 clinical trial of ISLA-101, page-45
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
-0.010(4.76%) |
Mkt cap ! $49.44M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 21.0¢ | 19.5¢ | $83.94K | 411.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 19162 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 41829 | 2 |
View Market Depth
| Last trade - 14.15pm 11/08/2025 (20 minute delay) ? |
| ILA (ASX) Chart |